ORAMED PHARMACEUTICALS Reports Third Quarter Earnings Results for Fiscal Year 2023
November 20, 2023
🌥️Earnings Overview
On November 9 2023, ORAMED PHARMACEUTICALS ($NASDAQ:ORMP) reported its earnings results for the third quarter of fiscal year 2023, which ended on September 30 of the same year. Total revenue for the quarter was USD 0.0 million, a substantial decrease of 100.0% compared to the same period in the previous year. The company reported a net income of -3.2 million, down from the -7.1 million reported in the corresponding quarter of the prior year.
Price History
The company’s stock opened at $2.0 and closed at $2.0, a drop of 5.8% from its previous closing price of 2.1. This decline was in line with the global market trend, as stock markets worldwide struggled in the face of global economic uncertainty. This was attributed to cost-cutting measures and efficiency improvements implemented by the company over the past few months.
Overall, ORAMED PHARMACEUTICALS‘ third quarter earnings results were below expectations, but the company remains optimistic about its future prospects. Despite the difficult economic climate, ORAMED PHARMACEUTICALS is confident that its cost-cutting initiatives and efficiency improvements will enable it to remain competitive in the long term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Oramed Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 2.02 | -16.35 | -778.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Oramed Pharmaceuticals. More…
| Operations | Investing | Financing |
| -16.94 | -91.78 | 81.15 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Oramed Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 230.89 | 82.66 | 3.7 |
Key Ratios Snapshot
Some of the financial key ratios for Oramed Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -9.3% | – | -797.5% |
| FCF Margin | ROE | ROA |
| -865.8% | -6.7% | -4.4% |
Analysis
As GoodWhale, we recently performed a comprehensive analysis of ORAMED PHARMACEUTICALS‘ wellbeing. The results of our Star Chart report showed that ORAMED PHARMACEUTICALS has an intermediate health score of 4/10 with regard to its cashflows and debt. This indicates that ORAMED PHARMACEUTICALS might be able to pay off debt and fund future operations. ORAMED PHARMACEUTICALS is classified as ‘elephant’, which is a type of company that we determined to have higher assets than liabilities. This could make ORAMED PHARMACEUTICALS attractive for certain kinds of investors. In particular, those interested in strong asset positions. However, ORAMED PHARMACEUTICALS is weak when it comes to dividend yields, profitability and growth. More…
Peers
The company has several competitors, such as Genovate Biotechnology Co Ltd, NervGen Pharma Corp, and Beijing Konruns Pharmaceutical Co Ltd. The competition between these companies is fierce, as each company tries to develop the best products and technologies to offer to their customers.
– Genovate Biotechnology Co Ltd ($TPEX:4130)
Genovate Biotechnology Co Ltd has a market cap of 2.48B as of 2022. The company’s Return on Equity is 0.44%. Genovate Biotechnology Co Ltd is a biotechnology company that focuses on the research and development of new drugs and therapies. The company’s main products are anticancer drugs and vaccines.
– NervGen Pharma Corp ($TSXV:NGEN)
NervGen Pharma Corp is a biotechnology company that focuses on the development of therapies for nervous system injuries and degenerative diseases. The company has a market capitalization of 102.45 million as of 2022 and a return on equity of -90.61%. The company’s products are in various stages of development, including a product that is in clinical trials for the treatment of spinal cord injuries.
– Beijing Konruns Pharmaceutical Co Ltd ($SHSE:603590)
Beijing Konruns Pharmaceutical Co Ltd has a market cap of 4.31B as of 2022. The company’s Return on Equity (ROE) is 3.39%.
Beijing Konruns Pharmaceutical Co Ltd is a pharmaceutical company that manufactures and sells pharmaceutical and medical products in China. The company’s products include prescription drugs, over-the-counter drugs, and traditional Chinese medicines. Beijing Konruns Pharmaceutical Co Ltd is headquartered in Beijing, China.
Summary
Investors should be aware of the latest earnings report from ORAMED PHARMACEUTICALS, as the company reported total revenue of USD 0.0 million for the quarter ending September 30th, 2023, representing a decrease of 100.0% compared to the prior year quarter. Additionally, the company reported a net income of -3.2 million, a decrease from the -7.1 million reported in the same quarter of the previous year. This news caused the stock price to move down the same day. As a result, investors should approach investing in ORAMED PHARMACEUTICALS with caution until further clarity is achieved on the company’s financial performance and outlook.
Related Posts
Recent Posts
